Last reviewed · How we verify
GSK Biologicals' Infanrix™
Infanrix™ stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis.
Infanrix™ stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis. Used for Prevention of diphtheria, tetanus, and pertussis in infants and young children.
At a glance
| Generic name | GSK Biologicals' Infanrix™ |
|---|---|
| Also known as | DTPa |
| Sponsor | GlaxoSmithKline |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
This vaccine contains inactivated toxins from the bacteria causing these diseases, which the immune system recognizes and mounts a response against, leading to immunity without causing the disease.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and young children
Common side effects
- Fever
- Injection site reactions (redness, swelling, pain)
Key clinical trials
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine (PHASE4)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women (PHASE4)
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (PHASE2)
- Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (PHASE3)
- A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy (PHASE4)
- Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery (PHASE4)
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' Infanrix™ CI brief — competitive landscape report
- GSK Biologicals' Infanrix™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI